Yoshiaki Shinden1, Sayuri Akiyoshi2, Hiroki Ueo3, Syo Nambara3, Tomoko Saito3, Hisateru Komatsu3, Masami Ueda3, Hidenari Hirata3, Shotaro Sakimura3, Ryutaro Uchi3, Yuki Takano3, Tomohiro Iguchi3, Hidetoshi Eguchi3, Keishi Sugimachi3, Yuko Kijima4, Hiroaki Ueo5, Shoji Natsugoe4, Koshi Mimori6. 1. Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan. 2. National Hospital Organization Kyushu Cancer Center, Minamiku, Fukuoka, Fukuoka, Japan. 3. Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan. 4. Department of Digestive Surgery, Breast and Thyroid Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Sakuragaoka, Kagoshima, Japan. 5. Ueo Breast Surgery Hospital, Haya, Oita, Japan. 6. Department of Surgery, Kyushu University Beppu Hospital, Beppu, Oita, Japan kmimori@beppu.kyushu-u.ac.jp.
Abstract
BACKGROUND/AIM: MiR-15a targets Cyclin E1 (CCNE1), which regulates the cell cycle and promotes cell proliferation and progression. Herein, we investigated the clinicopathological significance of miR-15a as a prognostic marker in breast cancer (BC) cases. MATERIALS AND METHODS: We collected primary tumor samples of 230 BC cases, including 68 triple-negative cases. The expression levels of miR-15a in primary tumors were measured by qRT-PCR assay. RESULTS: Low expression of miR-15a in primary tumors was significantly correlated with shorter disease-free survival (p=0.0012) and overall survival (p=0.005) compared to the high miR-15a expression in triple-negative BC cases. Multivariate analysis indicated that low miR-15a expression was an independent prognostic factor for overall survival [RR=2.56(1.03-7.18), p=0.04]. CONCLUSION: MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases. Copyright
BACKGROUND/AIM: MiR-15a targets Cyclin E1 (CCNE1), which regulates the cell cycle and promotes cell proliferation and progression. Herein, we investigated the clinicopathological significance of miR-15a as a prognostic marker in breast cancer (BC) cases. MATERIALS AND METHODS: We collected primary tumor samples of 230 BC cases, including 68 triple-negative cases. The expression levels of miR-15a in primary tumors were measured by qRT-PCR assay. RESULTS: Low expression of miR-15a in primary tumors was significantly correlated with shorter disease-free survival (p=0.0012) and overall survival (p=0.005) compared to the high miR-15a expression in triple-negative BC cases. Multivariate analysis indicated that low miR-15a expression was an independent prognostic factor for overall survival [RR=2.56(1.03-7.18), p=0.04]. CONCLUSION:MiR-15a expression levels could be a promising biological and prognostic marker for overall survival especially in triple-negative BC cases. Copyright
Authors: Yulian Mytsyk; Yuriy Borys; Lesia Tumanovska; Dmytro Stroy; Askold Kucher; Katarina Gazdikova; Luis Rodrigo; Peter Kruzliak; Robert Prosecky; Peter Urdzik; Victor Dosenko Journal: Clin Exp Med Date: 2019-08-22 Impact factor: 3.984
Authors: Yulian Mytsyk; Victor Dosenko; Yuriy Borys; Askold Kucher; Katarina Gazdikova; Dietrich Busselberg; Martin Caprnda; Peter Kruzliak; Ammad Ahmad Farooqi; Manyuk Lubov Journal: Int Urol Nephrol Date: 2018-03-16 Impact factor: 2.370
Authors: Yunke Song; Duncan Kilburn; Jee Hoon Song; Yulan Cheng; Christopher T Saeui; Douglas G Cheung; Carlo M Croce; Kevin J Yarema; Stephen J Meltzer; Kelvin J Liu; Tza-Huei Wang Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240
Authors: Julia Alejandra Pezuk; Thiago Luiz Araujo Miller; José Luiz Barbosa Bevilacqua; Alfredo Carlos Simões Dornellas de Barros; Felipe Eduardo Martins de Andrade; Luiza Freire de Andrade E Macedo; Vera Aguilar; Amanda Natasha Menardo Claro; Anamaria Aranha Camargo; Pedro Alexandre Favoretto Galante; Luiz F L Reis Journal: Oncotarget Date: 2017-09-11
Authors: Yihang Qi; Xiangyu Wang; Xiangyi Kong; Jie Zhai; Yi Fang; Xiaoxiang Guan; Jing Wang Journal: Cancer Cell Int Date: 2019-01-31 Impact factor: 5.722